Keiji Tasaka

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Prognostic Factors

Acute Lymphoblastic Leukemia

Top Venues

Pediatric blood & cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshinori Uchihara, Katsutsugu Umeda, Yosuke Yamada, Hiroaki Ito, Keiji Tasaka, Kiyotaka Isobe, Ryo Akazawa, Naoko Kawabata, Satoshi Saida, Itaru Kato, Hidefumi Hiramatsu, Takashi Noguchi, Akio Sakamoto, Yoshiki Arakawa, Ayumu Arakawa, Nobuyuki Yamamoto, Yosuke Hosoya, Suguru Uemura, Ken-Ichiro Watanabe, Hideki Sano, Takashi Taga, Junko Takita
MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma. Cancer science (2024)
Yuko Chiba, Keiji Tasaka, Kousaku Matsubara, Makiko Mori, Michiko Muraoka, Takayuki Hamabata, Seishiro Nodomi, Kenji Waki
Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2-month-old infant. Pediatric blood & cancer 71 (6) (2024)
Hirohito Kubota, Hiroo Ueno, Keiji Tasaka, Tomoya Isobe, Satoshi Saida, Itaru Kato, Katsutsugu Umeda, Mitsuteru Hiwatari, Daiichiro Hasegawa, Toshihiko Imamura, Nobuyuki Kakiuchi, Yasuhito Nannya, Seishi Ogawa, Hidefumi Hiramatsu, Junko Takita
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia. Blood advances 8 (5) (2024)
Hirohito Kubota, Hiroo Ueno, Keiji Tasaka, Tomoya Isobe, Satoshi Saida, Itaru Kato, Katsutsugu Umeda, Mitsuteru Hiwatari, Daiichiro Hasegawa, Toshihiko Imamura, Nobuyuki Kakiuchi, Yasuhito Nannya, Seishi Ogawa, Hidefumi Hiramatsu, Junko Takita
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia. Blood advances 8 (5) (2024)
Yuko Chiba, Keiji Tasaka, Kousaku Matsubara, Makiko Mori, Michiko Muraoka, Takayuki Hamabata, Seishiro Nodomi, Kenji Waki
Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2-month-old infant. Pediatric blood & cancer 71 (6) (2024)
Yuko Chiba, Keiji Tasaka, Kousaku Matsubara, Makiko Mori, Michiko Muraoka, Takayuki Hamabata, Seishiro Nodomi, Kenji Waki
Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2-month-old infant. Pediatric blood & cancer 71 (6) (2024)
Yuko Chiba, Keiji Tasaka, Kousaku Matsubara, Makiko Mori, Michiko Muraoka, Takayuki Hamabata, Seishiro Nodomi, Kenji Waki
Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2-month-old infant. Pediatric blood & cancer (2024)
Yuki Shino, Katsutsugu Umeda, Yoshinori Uchihara, Kazuki Mitani, Keiji Tasaka, Hideto Ogata, Hirokazu Kobushi, Satoshi Saida, Itaru Kato, Takeshi Yoshida, Atsushi Yokoyama, Hidefumi Hiramatsu, Junko Takita
Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura. Pediatric blood & cancer (2023)
Hirohito Kubota, Hiroo Ueno, Keiji Tasaka, Tomoya Isobe, Satoshi Saida, Itaru Kato, Katsutsugu Umeda, Mitsuteru Hiwatari, Daiichiro Hasegawa, Toshihiko Imamura, Nobuyuki Kakiuchi, Yasuhito Nannya, Seishi Ogawa, Hidefumi Hiramatsu, Junko Takita
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia. Blood advances (2023)
Hirokazu Kobushi, Satoshi Saida, Katsutsugu Umeda, Atsushi Iwai, Kagehiro Kozuki, Hirohito Kubota, Kuniaki Tanaka, Satoshi Obu, Yoshinori Uchihara, Keiji Tasaka, Itaru Kato, Hidefumi Hiramatsu, Junko Takita
High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric blood & cancer (2023)
Keiji Tasaka, Itaru Kato, Shunki Takeshita, Yu Yoshioka, Ayuko Usami, Yoshinori Uchihara, Ryo Akazawa, Tatsuya Kamitori, Satoshi Saida, Katsutsugu Umeda, Hidefumi Hiramatsu, Souichi Adachi, Junko Takita
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatric blood & cancer 70 (5) (2022)
Keiji Tasaka, Itaru Kato, Shunki Takeshita, Yu Yoshioka, Ayuko Usami, Yoshinori Uchihara, Ryo Akazawa, Tatsuya Kamitori, Satoshi Saida, Katsutsugu Umeda, Hidefumi Hiramatsu, Souichi Adachi, Junko Takita
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatric blood & cancer (2022)
Keiji Tasaka, Itaru Kato, Shunki Takeshita, Yu Yoshioka, Ayuko Usami, Yoshinori Uchihara, Ryo Akazawa, Tatsuya Kamitori, Satoshi Saida, Katsutsugu Umeda, Hidefumi Hiramatsu, Souichi Adachi, Junko Takita
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatric blood & cancer 70 (5) (2022)
Keiji Tasaka, Hiroo Ueno, Kai Yamasaki, Takahiro Okuno, Tomoya Isobe, Shunsuke Kimura, Katsutsugu Umeda, Junichi Hara, Seishi Ogawa, Junko Takita
Oncogenic FGFR1 mutation and amplification in common cellular origin in a composite tumor with neuroblastoma and pheochromocytoma. Cancer science 113 (4) (2022)
Satoshi Obu, Katsutsugu Umeda, Hiroo Ueno, Mari Sonoda, Keiji Tasaka, Hideto Ogata, Kagehiro Kouzuki, Seishiro Nodomi, Satoshi Saida, Itaru Kato, Hidefumi Hiramatsu, Tatsuya Okamoto, Eri Ogawa, Hideaki Okajima, Ken Morita, Yasuhiko Kamikubo, Koji Kawaguchi, Kenichiro Watanabe, Hideto Iwafuchi, Shigeki Yagyu, Tomoko Iehara, Hajime Hosoi, Tatsutoshi Nakahata, Souichi Adachi, Shinji Uemoto, Toshio Kitawaki, Junko Takita
CD146 is a potential immunotarget for neuroblastoma. Cancer science 112 (11) (2021)
Takashi Mikami, Itaru Kato, James Badger Wing, Hiroo Ueno, Keiji Tasaka, Kuniaki Tanaka, Hirohito Kubota, Satoshi Saida, Katsutsugu Umeda, Hidefumi Hiramatsu, Tomoya Isobe, Mitsuteru Hiwatari, Ai Okada, Kenichi Chiba, Yuichi Shiraishi, Hiroko Tanaka, Satoru Miyano, Yuki Arakawa, Koichi Oshima, Katsuyoshi Koh, Souichi Adachi, Keiko Iwaisako, Seishi Ogawa, Shimon Sakaguchi, Junko Takita
Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia. Cancer science (2021)